Our medical implants technology leverages nature-derived biopolymers to prevent postoperative adhesions, enhancing surgical outcomes by harnessing the anti-fibrinolytic properties of inherent phenolic compounds.
Headquarter Singapore |
Year founded 2019 (5 years) |
Funding status Private |
Company type SME |
QA/RA Assistant
The company is owned by individual shareholder(s), it has no corporate shareholder.
Revenue: | hidden.item |
Corporate-only access Contact us for a free demo now! | |
Share Capital - Ordinary shares: | hidden.item |
Sign up to view for free |
Company | Incorporation date | Country of Registration | Share capital | Local SIC |
---|---|---|---|---|
| 25 Jan 2021 | Singapore | SGD 100 | 72106: RESEARCH AND EXPERIMENTAL DEVELOPMENT ON MEDICAL SCIENCE |